JP2014520877A - ワクチン接種および診断適用におけるポリオーマウイルスjcペプチドおよびタンパク質 - Google Patents

ワクチン接種および診断適用におけるポリオーマウイルスjcペプチドおよびタンパク質 Download PDF

Info

Publication number
JP2014520877A
JP2014520877A JP2014520691A JP2014520691A JP2014520877A JP 2014520877 A JP2014520877 A JP 2014520877A JP 2014520691 A JP2014520691 A JP 2014520691A JP 2014520691 A JP2014520691 A JP 2014520691A JP 2014520877 A JP2014520877 A JP 2014520877A
Authority
JP
Japan
Prior art keywords
protein
jcv
pml
cells
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014520691A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014520877A5 (cg-RX-API-DMAC7.html
Inventor
イリヤス イェルツィク,
ローラント マルティン,
スフェン シプリンク,
ミレイヤ ゾスペドラ,
ザーラ ユーゼフ,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zurich Universität
Original Assignee
Zurich Universität
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zurich Universität filed Critical Zurich Universität
Publication of JP2014520877A publication Critical patent/JP2014520877A/ja
Publication of JP2014520877A5 publication Critical patent/JP2014520877A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2014520691A 2011-07-22 2012-07-23 ワクチン接種および診断適用におけるポリオーマウイルスjcペプチドおよびタンパク質 Pending JP2014520877A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11006031A EP2548567A1 (en) 2011-07-22 2011-07-22 Polyoma virus JC peptides and proteins in vaccination and diagnostic applications
EP11006031.6 2011-07-22
PCT/EP2012/064445 WO2013014134A2 (en) 2011-07-22 2012-07-23 Polyoma virus jc peptides and proteins in vaccination and diagnostic applications

Publications (2)

Publication Number Publication Date
JP2014520877A true JP2014520877A (ja) 2014-08-25
JP2014520877A5 JP2014520877A5 (cg-RX-API-DMAC7.html) 2015-09-10

Family

ID=46548481

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014520691A Pending JP2014520877A (ja) 2011-07-22 2012-07-23 ワクチン接種および診断適用におけるポリオーマウイルスjcペプチドおよびタンパク質

Country Status (12)

Country Link
US (1) US9738690B2 (cg-RX-API-DMAC7.html)
EP (2) EP2548567A1 (cg-RX-API-DMAC7.html)
JP (1) JP2014520877A (cg-RX-API-DMAC7.html)
KR (1) KR20140062702A (cg-RX-API-DMAC7.html)
CN (1) CN103826653A (cg-RX-API-DMAC7.html)
AU (1) AU2012288955B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014001516A2 (cg-RX-API-DMAC7.html)
CA (1) CA2842543A1 (cg-RX-API-DMAC7.html)
EA (1) EA201490322A1 (cg-RX-API-DMAC7.html)
HK (1) HK1198517A1 (cg-RX-API-DMAC7.html)
MX (1) MX2014000776A (cg-RX-API-DMAC7.html)
WO (1) WO2013014134A2 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150065367A1 (en) * 2011-12-12 2015-03-05 Janssen Diagnostics Bvba Polyomavirus peptide sequences
US10300116B2 (en) 2013-06-10 2019-05-28 Ansun Biopharma, Inc. Treatment for BK polyomavirus infection
US9931393B2 (en) 2013-12-20 2018-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogenic JC polyomavirus compositions and methods of use
EP2926831A1 (en) * 2014-03-31 2015-10-07 Ruprecht-Karls-Universität Heidelberg CD8+ T-cell epitopes from polyomavirus capsid protein VP1 for vaccination
WO2016073595A1 (en) * 2014-11-05 2016-05-12 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services T cells and dendritic cells for polyomavirus therapy
WO2016104046A1 (ja) * 2014-12-22 2016-06-30 日東電工株式会社 透明導電性フィルム
IT201600083859A1 (it) * 2016-08-09 2018-02-09 Univ Degli Studi Di Ferrara Immunosaggio per l’identificazione di anticorpi contro il virus Polioma JC (JCPyV) mediante l’uso di peptidi sintetici.
CN113278634B (zh) 2020-11-16 2022-06-28 艾棣维欣(苏州)生物制药有限公司 一种预防和治疗默克尔细胞癌的新型疫苗

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0967397A (ja) * 1995-06-23 1997-03-11 Eisai Co Ltd 抗jcウイルス抗体
JP2000500973A (ja) * 1995-11-22 2000-02-02 ドイチェス プリマーテンツェントルム ゲゼルシャフト ミット ベシュレンクテル ハフツング Jc−ウイルスのvp−抗原
JP2003061693A (ja) * 2001-06-28 2003-03-04 Jenapharm Gmbh & Co Kg ウイルス様粒子、その製造方法およびその使用
JP2005341864A (ja) * 2004-06-02 2005-12-15 Japan Science & Technology Agency Jcウイルスの粒子形成阻害剤
WO2008091398A2 (en) * 2006-08-31 2008-07-31 Baylor Research Institute Jc virus vaccine
WO2010090757A1 (en) * 2009-02-05 2010-08-12 Biogen Idec Ma Inc. Methods for the detection of jc polyoma virus

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4840792B2 (ja) 2001-11-22 2011-12-21 独立行政法人科学技術振興機構 JCウイルスagnoを対象としたPMLの治療
AU2003238008A1 (en) 2002-06-12 2003-12-31 Temple University Of The Commonwealth System Of Higher Education Method of cell growth inhibition with agnoprotein
US7468186B2 (en) * 2005-07-22 2008-12-23 City Of Hope Polyomavirus cellular epitopes and uses therefor
CN100595765C (zh) * 2008-06-30 2010-03-24 腾讯科技(深圳)有限公司 基于媒体播放器的关键词内容发布方法及系统
WO2010099205A1 (en) 2009-02-24 2010-09-02 The Trustees Of The University Of Pennsylvania Methods for treating progressive multifocal leukoencephalopathy (pml)
EP2226392A1 (en) * 2009-03-03 2010-09-08 Assistance Publique - Hôpitaux de Paris Method for detecting JCV infection
WO2011124652A1 (en) * 2010-04-08 2011-10-13 Fondazione Centro San Raffaele Del Monte Tabor Immunodominant peptide of polyomavirus jc and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0967397A (ja) * 1995-06-23 1997-03-11 Eisai Co Ltd 抗jcウイルス抗体
JP2000500973A (ja) * 1995-11-22 2000-02-02 ドイチェス プリマーテンツェントルム ゲゼルシャフト ミット ベシュレンクテル ハフツング Jc−ウイルスのvp−抗原
JP2003061693A (ja) * 2001-06-28 2003-03-04 Jenapharm Gmbh & Co Kg ウイルス様粒子、その製造方法およびその使用
JP2005341864A (ja) * 2004-06-02 2005-12-15 Japan Science & Technology Agency Jcウイルスの粒子形成阻害剤
WO2008091398A2 (en) * 2006-08-31 2008-07-31 Baylor Research Institute Jc virus vaccine
WO2010090757A1 (en) * 2009-02-05 2010-08-12 Biogen Idec Ma Inc. Methods for the detection of jc polyoma virus

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CYTHERIS THE IMMUNE ENHANCING COMPANY: "CYTHERIS ANNOUNCES PUBLICATION OF CLINICAL CASE STUDY COMBINING RECOMBINANT HUMAN INTERLEUKIN-7 (CYT", [ONLINE], JPN5014008768, 30 November 2010 (2010-11-30), ISSN: 0003324165 *
JOURNAL OF VIROLOGY, vol. 73, no. 5, JPN6017011797, 1999, pages 4465 - 4469, ISSN: 0003532720 *
MONIUSZKO MARCIN: "RECOMBINANT INTERLEUKIN-7 INDUCES PROLIFERATION OF NAIVE MACAQUE CD4+ AND CD8+ T CELLS IN VIVO", JOURNAL OF VIROLOGY, vol. V78 N18, JPN5014008767, September 2004 (2004-09-01), pages 9740 - 9749, ISSN: 0003324164 *
PATEL AMILA: "TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY AND IDIOPATHIC CD4+ LYMPHOCYTOPENIA", JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, vol. V65 N12, JPN5014008766, December 2010 (2010-12-01), pages 2489 - 2492, ISSN: 0003324163 *
TAN C S: "PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY AND OTHER DISORDERS CAUSED BY JC VIRUS: 以下備考", LANCET NEUROLOGY, vol. V9 N4, JPN5014008771, 1 April 2010 (2010-04-01), GB, pages 425 - 437, ISSN: 0003324162 *

Also Published As

Publication number Publication date
US9738690B2 (en) 2017-08-22
MX2014000776A (es) 2014-11-26
CN103826653A (zh) 2014-05-28
CA2842543A1 (en) 2013-01-31
KR20140062702A (ko) 2014-05-26
AU2012288955B2 (en) 2017-06-08
WO2013014134A2 (en) 2013-01-31
WO2013014134A3 (en) 2013-05-02
BR112014001516A2 (pt) 2017-02-14
AU2012288955A1 (en) 2014-02-20
EP2548567A1 (en) 2013-01-23
HK1198517A1 (en) 2015-05-15
EP2734218A2 (en) 2014-05-28
NZ620196A (en) 2016-10-28
US20140356320A1 (en) 2014-12-04
EA201490322A1 (ru) 2014-05-30

Similar Documents

Publication Publication Date Title
Yang et al. Adoptive therapy with amyloid-β specific regulatory T cells alleviates Alzheimer's disease
AU2012288955B2 (en) Polyoma virus JC peptides and proteins in vaccination and diagnostic applications
Aly et al. Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome
RU2721574C2 (ru) Вакцинная композиция против злокачественной опухоли
US7202034B2 (en) Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses
US20230172986A1 (en) Treatment and prevention of alloreactivity using virus-specific immune cells expressing chimeric antigen receptors
TWI841576B (zh) 用於治療傳染病之共受體系統
US20160032245A1 (en) Compositions and Methods for Modulating an Immune Response
Anwar Jagessar et al. The different clinical effects of anti-BLyS, anti-APRIL and anti-CD20 antibodies point at a critical pathogenic role of γ-herpesvirus infected B cells in the marmoset EAE model
JP2015133982A (ja) 特異抗原に活性化したcd4+、cd25+t細胞
US20240376429A1 (en) Virus-specific immune cells expressing chimeric antigen receptors
JP7495137B2 (ja) 癌抗原特異的細胞傷害性t細胞
JP5626990B2 (ja) Th2細胞誘導用組成物およびTh2型疾患の治療組成物、ならびにこれらの利用
AU4848899A (en) Methods and agents for the detection and modulation of cellular immunity to immune privileged antigens
EP3915575A1 (en) Vaccine formulations
NZ620196B2 (en) Polyoma virus jc peptides and proteins in vaccination and diagnostic applications

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150723

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150723

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160526

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160825

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170404

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170629

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170901

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171228